Literature DB >> 10498293

Antimuscarinic, calcium channel blocker and tachykinin NK2 receptor antagonist actions of otilonium bromide in the circular muscle of guinea-pig colon.

P Santicioli1, V Zagorodnyuk, A R Renzetti, C A Maggi.   

Abstract

We have analyzed, by the sucrose gap method, the action of otilonium bromide, a quaternary ammonium derivative in use for the symptomatic therapy of irritable bowel syndrome, on the electrical and mechanical responses initiated by different stimuli in the circular muscle of the guinea-pig proximal colon. Otilonium bromide produced a concentration-dependent inhibition of membrane depolarization (IC50 4.1 microM), action potentials (APs) and contraction (IC50 3.7 microM) produced by the muscarinic receptor agonist, methacholine. It also produced a concentration-dependent inhibition of APs and accompanying contraction (IC50 31 microM) produced by KCl (30 mM), and had a biphasic effect on the cholinergic excitatory junction potential (e.j.p.) produced by single pulse electrical field stimulation: at low concentrations (0.1-0.3 microM) otilonium bromide enhanced the e.j.p. and, at higher concentrations (IC50 22 microM and 16 microM toward depolarization and contraction), produced a concentration-dependent inhibition. Otilonium bromide eliminated the APs superimposed on the depolarization induced by the tachykinin NK1 receptor agonist, [Sar9]substance P-sulphone and suppressed the corresponding contraction (IC50 43 microM) but had little effect on the sustained membrane depolarization induced by this agonist. On the other hand, otilonium bromide produced a similar inhibitory effect on both membrane depolarization and contraction (IC50 38 microM and 45 microM, respectively) induced by the tachykinin NK2 receptor agonist [betaAla8]neurokinin A (4-10). When tested in the presence of nifedipine (1 microM), otilonium bromide had no effect on the membrane depolarization induced by [Sar9]substance P-sulphone but inhibited in a concentration-dependent manner the depolarization induced by [betaAla8]neurokinin A (4-10) (IC50 41 microM). In contrast, the blocker of receptor-operated cation channels, SKF 96365, inhibited with similar potency the depolarization induced by both [Sar9]substance P-sulphone and [betaAla8]neurokinin A (4-10) (IC50 60 microM and 54 microM, respectively). In radioligand binding experiments otilonium bromide produced a concentration-dependent inhibition of the binding of both an agonist ([125I]neurokinin A, Ki 7.2 microM) and an antagonist ([3H]SR 48968, Ki 2.2 microM) to membranes of Chinese hamster ovary cells transfected with the human tachykinin NK2 receptor. In conclusion, the present findings demonstrate that, in the microM range of concentrations, otilonium bromide acts as a muscarinic and tachykinin NK2 receptor antagonist and as a calcium channel blocker. The latter property is likely to account for its ability to suppress contraction initiated by the tachykinin NK1 receptor agonist. Therefore multiple mechanisms of action account for the ability of otilonium bromide to reduce stimulated motility of intestinal smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498293     DOI: 10.1007/pl00005370

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  12 in total

1.  Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.

Authors:  G Cipriani; S J Gibbons; S A Saravanaperumal; J Malysz; L Sha; J H Szurszewski; D R Linden; S Evangelista; M S Faussone-Pellegrini; M G Vannucchi; G Farrugia
Journal:  Neurogastroenterol Motil       Date:  2015-04-30       Impact factor: 3.598

Review 2.  Irritable bowel syndrome.

Authors:  Antonella Spinelli
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  T-type Ca(2+) channel modulation by otilonium bromide.

Authors:  Peter R Strege; Lei Sha; Arthur Beyder; Cheryl E Bernard; Edward Perez-Reyes; Stefano Evangelista; Simon J Gibbons; Joseph H Szurszewski; Gianrico Farrugia
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-04       Impact factor: 4.052

4.  The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts.

Authors:  Susanne Lindqvist; James Hernon; Paul Sharp; Neil Johns; Sarah Addison; Mark Watson; Richard Tighe; Shaun Greer; Jean Mackay; Michael Rhodes; Michael Lewis; William Stebbings; Chris Speakman; Stefano Evangelista; Ian Johnson; Mark Williams
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

5.  Effects of the Calcium Channel Blocker Otilonium Bromide on Seizure Activity in Rats With Pentylenetetrazole-Induced Convulsions.

Authors:  Arife Erdogan; Mumin Alper Erdogan; Ozum Atasoy; Oytun Erbas
Journal:  Neurochem Res       Date:  2021-04-03       Impact factor: 3.996

Review 6.  Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.

Authors:  Jakub Rychter; Francisco Espín; Diana Gallego; Patri Vergara; Marcel Jiménez; Pere Clavé
Journal:  Therap Adv Gastroenterol       Date:  2014-07       Impact factor: 4.409

Review 7.  IBS and the role of otilonium bromide.

Authors:  Guy Boeckxstaens; Enrico S Corazziari; Fermín Mearin; Jan Tack
Journal:  Int J Colorectal Dis       Date:  2012-11-22       Impact factor: 2.571

Review 8.  Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome.

Authors:  Alessandro Lecci; Angela Capriati; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

9.  Preparation and characterization of reconstructed small intestinal brush border membranes for surface plasmon resonance analysis.

Authors:  Sungpil Cho; Jae Hyung Park; Jaehoon Yu; Yong-Kyu Lee; Youngro Byun; Hesson Chung; Ick Chan Kwon; Seo Young Jeong
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

10.  Irritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity.

Authors:  Ashley L Cunningham; Orhi Esarte Palomero; Bradley J Voss; M Stephen Trent; Bryan W Davies
Journal:  Antimicrob Agents Chemother       Date:  2021-07-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.